Abstract
Abstract
p17 matrix protein released by HIV+ cells interacts with leukocytes heparan sulfate proteoglycans (HSPGs), CXCR1 and CXCR2 exerting different cytokine-like activities that contribute to AIDS pathogenesis. Since the bioactive form of several cytokines is represented by dimers/oligomers and oligomerization is promoted by binding to heparin or HSPGs, here we evaluated if heparin/HSPGs also promote p17 oligomerization. Heparin favours p17 dimer, trimer and tetramer assembly, in a time- and biphasic dose-dependent way. Heparin-induced p17 oligomerization is of electrostatic nature, being it prevented by NaCl, by removing negative sulfated groups of heparin and by neutralizing positive lysine residues in the p17 N-terminus. A new computational protocol has been implemented to study heparin chains up to 24-mer accommodating a p17 dimer. Molecular dynamics show that, in the presence of heparin, two p17 molecules undergo conformational modifications creating a continuous “electropositive channel” in which heparin sulfated groups interact with p17 basic amino acids, promoting its dimerization. At the cell surface, HSPGs induce p17 oligomerization, as demonstrated by using B-lymphoblastoid Namalwa cells overexpressing the HSPG Syndecan-1. Also, HSPGs on the surface of BJAB and Raji human B-lymphoblastoid cells are required to p17 to induce ERK1/2 activation, suggesting that HS-induced oligomerization plays a role in p17-induced lymphoid dysregulation during AIDS.
Funder
Consiglio Nazionale delle Ricerche
Ministero dell'Istruzione, dell'Università e della Ricerca
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Bryant, M. & Ratner, L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 87, 523–527 (1990).
2. Cannon, P. M. et al. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J Virol 71, 3474–3483 (1997).
3. Fiorentini, S., Giagulli, C., Caccuri, F., Magiera, A. K. & Caruso, A. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacology & therapeutics 128, 433–444 (2010).
4. Zeinolabediny, Y. et al. HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders. Scientific reports 7, 10313 (2017).
5. Li, S., Bozzo, L., Wu, Z., Lu, W. & Romerio, F. The HIV-1 matrix protein p17 activates the transcription factors c-Myc and CREB in human B cells. The new microbiologica 33, 13–24 (2010).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献